CN1040063C - Zinc gluconate for calming sathma and cough - Google Patents
Zinc gluconate for calming sathma and cough Download PDFInfo
- Publication number
- CN1040063C CN1040063C CN92111820A CN92111820A CN1040063C CN 1040063 C CN1040063 C CN 1040063C CN 92111820 A CN92111820 A CN 92111820A CN 92111820 A CN92111820 A CN 92111820A CN 1040063 C CN1040063 C CN 1040063C
- Authority
- CN
- China
- Prior art keywords
- zinc gluconate
- cough
- zinc
- effect
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a new application of zinc gluconate which not only is a supplemental agent of the trace element of zinc, but also has the function of relieving asthma and cough. The zinc gluconate is applied to the treatment for asthmatic bronchitis, tussis and upper respiratory disease patients whose symptoms are obviously reduced after 10 to 20 minutes after the zinc gluconate is orally taken, and particularly, asthmatic trachitis patients have obvious comfortable sense in the breast after the zinc gluconate is orally taken. Pharmacological and medicine effect experiments prove that the asthma relieving action of the zinc gluconate is better than that of aminophylline, and the cough relieving action is slightly better than that of toclase. The zinc gluconate has the advantages of rich medicine source, simple manufacturing technique, low price, convenient and safe use and no toxic or side effect when a conventional dosage is used. The new discovery of the function of relieving asthma and cough of the zinc gluconate realizes that the zinc gluconate can treat new indications in the aspect of medicine treatment, so favorable economic and social benefits can be obtained.
Description
The present invention relates to the application of a kind of zinc gluconate in cough medicine is relievingd asthma in preparation.
Zinc gluconate is a kind of complement agent of trace element zinc preferably.Trace element zinc is one of nutrition of needed by human, and it participates in the nearly all metabolic process of cell.Knownly there is the activity of 80 kinds of enzymes relevant according to the present with zinc.Zinc is as using separately active drug in recent years, be widely used in research that scientific research, nutrition and clinical practice, particularly zinc and immunity, tumor concern the aspect particularly medical circle gaze at.Zinc gluconate is the agent of a kind of zinc preferably.It does not have the gastrointestinal reaction of zinc sulfate sample, and its application is general day by day abroad.The literature review of 1989 the 24th people's reports " clinical practice of zinc gluconate and untoward reaction " such as volume o. 11th " Chinese medicine magazine " Xi'an Hao Ya of pharmaceutical factory of medical university brightness, introduced zinc gluconate and at present clinically be mainly used in zinc supplement, antiviral, treatment common cold, intestinal originality acrodermatitis (AE), improve cancer and the relevant syndrome patient's of AIDS immunologic function.The zinc deficiency retinal function obstacle that Chohn ' s disease is concurrent, the concurrent hyperprolactinemia of male's uremic patient, multiple sclerosis, dermatopathy etc. all have better curative effect.Its treatment disease mechanisms it be not immediately clear and remains to be furtherd investigate.People such as volume " Guangdong College of Medical Pharmacy's journal " Zhong Shi reported when suffering from chronic obstructive pulmonary disease in 1988 4, and lipid peroxide increases in patient's body, causes the copper height and the zinc-iron reduction and the antioxidant reductase level descends and trace element is out of proportion.4:197 " foreign medical science department of dermatologry fascicle " Tan third constellations in 1980 report zinc itself has certain anti-inflammatory, may be to borrow the stabilate film, and what the histamine that suppresses mastocyte discharged or influenced macrophage engulfs activity etc. and role." Puscas let al:Int JPharm Ther and Toxic " 1,985 23 (11): 609, report zinc sulfate has the antihistaminic effect.
The objective of the invention is to the zinc gluconate drug effect be done further research according to reported in literature, for being used to prepare the cough medicine of relievining asthma, zinc gluconate provides new application approach, the inventor is in respiratory system diseases such as clinical treatment old-slow-bronchial tube and zinc deficiency lysis for this reason, find to mend behind the zinc gluconate its chronic bronchitis that occurs together and bronchial asthma are had fabulous curative effect, still be not reported in this relevant at home and abroad document, in order to verify whether zinc gluconate has the new function of the antitussive of relievining asthma, the inventor has done following experiments in conjunction with actual conditions, now the result is summarized as follows:
One, pant due to zinc gluconate is sprayed respectively to acetylcholine and the histamine influence of model:
With 2% acetylcholine and 0.3% histamine spray respectively cause two groups of Cavia porcelluss " outbreak of panting " with dyspnea, to fall down to the ground be index, has with zinc gluconate 30mg/kg lumbar injection and relieving asthma significantly and protective effect, compares P＜0.01 with matched group.
Two, zinc gluconate and aminophylline antiasthmatic effect are relatively:
Zinc gluconate 30mg/kg, its effect of relievining asthma does not have significant difference (P＞0.05) with aminophylline 60mg/kg but compares then with aminophylline 30mg/kg that its effect of relievining asthma obviously is better than aminophylline (P＜0.01)
Three, zinc gluconate and phenytoin Sodium antiasthmatic effect are relatively:
Zinc gluconate 30mg/kg compares with phenytoin Sodium 30mg/kg, the two there was no significant difference (P＞0.05), but point out the two antiasthmatic effect, all be better than aminophylline.
Four, the antiasthmatic effect of zinc gluconate various dose is relatively:
Experimental result shows: the antiasthmatic effect of zinc gluconate 60mg/kg obviously is better than 30mg/kg.
Five, zinc gluconate and isoproterenol respectively atomized medicine introducing acetylcholine and histamine are mixed sucked and cause the influence of asthmatic model:
Experimental result shows, zinc gluconate group and isoproterenol group there was no significant difference (P＞0.05).
Six, zinc gluconate is to the influence of Guinea pig lung overflow experiment:
Experimental result shows bronchial smooth muscle that a zinc gluconate 10mg/ intravenous injection can the integral body that 20 a μ g/ intravenous injection cause to the antihistaminic fully overflow phenomena due to shrinking.
Seven, zinc gluconate is to the laboratory observation of the lung airway perfusion that exsomatizes:
Experimental result shows that zinc gluconate does not have the effect of loose isolated bronchia smooth muscle.(the different third kidney group then can).
Eight, zinc gluconate is to the influence of isolated smooth muscle:
Experimental result shows: the zinc gluconate of big concentration can not resist by the caused bronchial muscular spasm of acetylcholine or histamine (add respectively atropine or diphenhydramine then can).
Nine, zinc gluconate and share other drug acetylcholine and histamine mixed aerosol are sucked the comparison that causes the effect of panting:
Result's demonstration (one) zinc gluconate 60mg/kg group is compared its effect there was no significant difference (P＞0.05) with zinc gluconate 30mg/kg+ phenytoin Sodium 30mg/kg group.(2) zinc gluconate 60mg/kg group is compared with zinc gluconate 30mg/kg+ doxepin 20mg/kg group, and its effect is there was no significant difference (P＞0.05) also, and this points out rational compound recipe to form foundation to us.
Ten, zinc gluconate is to the laboratory observation of Cavia porcellus antitussive effect:
Suck with 17.5% citric acid solution atomizing and to cause cough model, zinc gluconate 30mg/kg lumbar injection is compared by relatively reaching with carbetapentane citrate group (8mg/kg) before and after the body and function medicine, all showing good antitussive effect, the P value is respectively＜and 0.01 and＜0.05.The antitussive effect of zinc gluconate slightly is better than carbetapentane citrate.
Experimental result shows: though zinc gluconate very high concentration isolated airway smooth muscle is not had direct diastole effect, and also do not have blocking-up M and H receptor acting, but, illustrate that zinc gluconate does not also have effect to beta receptor because isoproterenol is effective to above-mentioned model.
Can conclude that in sum zinc gluconate truly has good relievining asthma, antitussive effect, its mechanism of action may be to need by whole neurohumoral adjusting, particularly finish by histamine's release of stabilate film, inhibition mastocyte.
The zinc gluconate of the present invention antitussive new drug of relievining asthma has following three kinds of dosage forms:
1, tablet: every contains zinc gluconate 50～200mg
Prescription: zinc gluconate 50～200mg
Icing Sugar is an amount of
Starch is an amount of
HPMC or other fiber type are plain an amount of
5% gelatinized corn starch is an amount of
Method: zinc gluconate is added wetting agent after with the adjuvant mix homogeneously, granulate in 16～18 order nylon wires in dry below 45 ℃, again through 14～16 order net granulate, by the stamping of flat circle, sheet weighs 0.1～0.2g.
2, electuary: every bag 5～6 gram contains zinc gluconate 50～200mg
Prescription: zinc gluconate 50～200mg
White sugar is an amount of
Distilled water is an amount of
Method: with behind the white sugar crushing screening with the abundant mix homogeneously of zinc gluconate, adding distil water is made soft material, granulates in 14～18 order nylon wires, and is dry below 45 ℃, 14～16 order net granulate, packing.
3, capsule: every contains zinc gluconate 50～200mg
Prescription: zinc gluconate 50～200mg
Icing Sugar is an amount of
Starch is an amount of
HPMC or other fiber type are plain an amount of
5% gelatinized corn starch is an amount of
Method: will add wetting agent behind the main ingredient mix homogeneously, in 16～18 order nylon wires, granulate, dry below 45 ℃, through 14～16 order net granulate, encapsulated.
The zinc gluconate usage: this medicine is oral medicine, to the general one after each meal of old-slow-bronchial tube patient, and every day three times, each 150～250mg, the clothes back is after 10～20 minutes, and patient's chest promptly has obvious happy sensation, and serveing on a few days symptom can disappear.
The new purposes of zinc gluconate of the present invention has following effect:
1, the innovation of the antitussive function of relievining asthma of zinc gluconate is found, makes it increase new indication on Drug therapy.
2, the present invention finds that through the pharmacological effect experiment antiasthmatic effect is better than aminophylline, and antitussive effect slightly is better than carbetapentane citrate.
3, medicine of the present invention source is abundant, and manufacturing process is simple, cheap, easy to use safety, nontoxic, the side effect of conventional amount used.
4, old-slow-bronchial tube is national common disease, frequently-occurring disease, and the present invention necessarily has good economic benefit and social benefit as a kind of new drug of treatment respiratory system.
Embodiment:
One, zinc gluconate animal experiment (part):
Zinc gluconate (is called for short TX, provide by the Xinghuo Parmaceutical Factory, Datong City down together), in clinical application, find, this medical instrument has good antiasthmatic effect, for making it clinically early to the respiratory system transition, increase the medication effect of respiratory system disease, we have observed the relievining asthma of TX, antitussive, expectorant functions on laboratory animal.
The Cavia porcellus influence of model of panting due to experiment one, TX suck acetylcholine atomizing:
Method: select body weight 180～220g to 30 of the Cavia porcelluss of acetylcholine sensitivity, the male and female dual-purpose, be divided into three groups at random, it is TX group (30mg/kg), aminophylline group (60mg/kg), the normal saline group, three treated animals are intraperitoneal injection of drugs 0.5ml respectively, after 30 minutes, to atomizing case internal spraying 2% acetylcholine solution, speed is the 2ml/ branch with CSW-A type soniclizer, time is 10 seconds, three treated animals are placed simultaneously in the atomizing case thereupon, observe incubation period and quantity thereof that panting appears in animal, dyspnea to occur, tic falls down to the ground and is the generation of panting, and the person of panting do not occur for suppressing fully in six minutes.
The result: visible TX has good antiasthmatic effect by table 1.
The influence that table 1 TX pants to acetylcholine atomizing imbedibility:
Number of animals suppresses number average latency P value normal saline group 10 0 55 ± 12.7TX fully and organizes 10 6*, 245 ± 149*＜0.05 aminophylline group, 10 7*, 271 ± 145*＜0.05 remarks: after experiment finishes, dead 5 of saline group, TX group and aminophylline group there is no death.
Experiment 2.The effect that Cavia porcellus panted due to TX and phenytoin Sodium sucked acetylcholine atomizing is relatively:
Method: with experiment 1, divide three groups at random, be respectively the normal saline group, TX organizes (30mg/kg), phenytoin Sodium group (30mg/kg).
The result: be shown in Table 2, the antiasthmatic effect difference of TX and phenytoin Sodium does not have significance.
The effect that table 2 TX and phenytoin Sodium are panted to Cavia porcellus due to the acetylcholine relatively
Number of animals suppresses number average latency P value fully
Normal saline group 10 0 68 ± 33
TX organizes 10 7*, 271 ± 143*＜0.05
Phenytoin Sodium group 10 9* 336 ± 74*＜0.05
Remarks: compare with the normal saline group * P＜0.05
The TX group compares P＞0.05 with the phenytoin Sodium group
After the off-test, dead 4 of normal saline group, dead 1 of phenytoin Sodium group, the TX group does not have dead.
Experiment 3:TX brings out guinea pig cough's effect to citric acid
Method: choosing is to 20 of the responsive Cavia porcelluss of citric acid, be divided into TX (30mg/kg) group and normal saline group at random, each 10, earlier with CSW-A type ultrasound atomizer with 2ml/ minute speed to atomizing case internal spraying 17.5% citric acid solution 1 minute, put into animal thereupon, write down every animal cough number of times in 5 minutes, the administration respectively of above-mentioned two days later two treated animals, the 40th minute repeated experiments behind the medicine, write down every animal cough number of times, relatively the cough number of times behind two treated animals cough number of times and the every treated animal medicine prodrug in 5 minutes again.Result: guinea pig cough's model due to the citric acid is had protective effect by the visible TX of table 4.
The influence of guinea pig cough's number of times due to table 4 TX sucks citric acid atomizing:
Cough number of times P value normal saline group 23.2 ± 6.4 22.1 ± 7.9＞0.05TX group 27.2 ± 10.2 10.3 ± 6.3＜0.01P value＜0.01 behind the cough number of times medicine before the medicine
Test 4 TX and carbetapentane citrate antitussive effect relatively
Method with experiment 3, is divided three groups, normal saline group, TX (30mg/kg) group, and carbetapentane citrate (8mg/kg) group, intraperitoneal injection was tested after 40 minutes.The result: seeing Table 5, two medicines all has antitussive effect, and the TX effect is better than carbetapentane citrate.The effect of guinea pig cough's number of times relatively due to table 5 TX and carbetapentane citrate sucked citric acid atomizing
Cough number of times P value in the number of animals 5 minutes
Normal saline group 10 22.4 ± 6.6
TX organizes 10 4.5 ± 3.1*＜0.05
Carbetapentane citrate group 10 10.0 ± 3.9*＜0.05
Two, clinical practice (enumerating two examples):
1,38 years old cadre of Sun Baolin man
People from Datong City, Shanxi Province
No. 12 institute 27 families, city, playground
Symptom: flu, cough, white expectorant, pant.Disease time is 7 days.It is invalid that intensified loquet distillate, compound sulfamethoxazole sheet and tangerine peel bolus 3 days were once taken in morbidity beginning, and pant, cough, costalgia, uncomfortable in chest, change clothes " lung treasured triple effect sheet " 3 days, poor effect.Numeration of leukocyte 10,000/mm
3Below.
Diagnosis: asthmatic bronchitis.
Treatment: oral zinc gluconate 200mg/ time, every day three times.
Patient's reaction: take zinc gluconate 200mg, 10 minutes aftersensation symptoms are breathed happy.Cough stops.Take recovery from illness in 2 days continuously.
2, Liu * *: man 82 years old
People from Datong City, Shanxi Province workman
No. four institutes in three Dao Ying mills, city
Symptom: cough, asthma, excessive phlegm are the senile chronic bronchitis patient, and dependence is throughout the year taken " the precious triple effect sheet of lung " and kept.Recently cold symptoms increases the weight of, dyspnea, and wheezing sound is obvious.
Treatment: oral zinc gluconate sheet 200mg/ time, every day three times.
Patient reaction: take 200mg first, after 20 minutes, breathes unobstructed, the wheezing sound disappearance.Cough alleviates.General Symptoms takes a turn for the better, and takes continuously and keeps, and is without any side effects.
Claims (1)
1, the application of zinc gluconate in cough medicine is relievingd asthma in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN92111820A CN1040063C (en) | 1992-12-30 | 1992-12-30 | Zinc gluconate for calming sathma and cough |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN92111820A CN1040063C (en) | 1992-12-30 | 1992-12-30 | Zinc gluconate for calming sathma and cough |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1074607A CN1074607A (en) | 1993-07-28 |
| CN1040063C true CN1040063C (en) | 1998-10-07 |
Family
ID=4945537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN92111820A Expired - Fee Related CN1040063C (en) | 1992-12-30 | 1992-12-30 | Zinc gluconate for calming sathma and cough |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1040063C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1303989C (en) * | 2004-10-25 | 2007-03-14 | 北京科信必成医药科技发展有限公司 | Zinc gluconate oral disintegrating tablet and its preparation process |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748783A (en) * | 2016-03-11 | 2016-07-13 | 济南正骐生物科技有限公司 | Drug for treating asthma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503070A (en) * | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
-
1992
- 1992-12-30 CN CN92111820A patent/CN1040063C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503070A (en) * | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1303989C (en) * | 2004-10-25 | 2007-03-14 | 北京科信必成医药科技发展有限公司 | Zinc gluconate oral disintegrating tablet and its preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1074607A (en) | 1993-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1136874C (en) | Composite medicine for treating hyperlipemia | |
| CN1403138A (en) | Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process | |
| CN1040063C (en) | Zinc gluconate for calming sathma and cough | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1810268A (en) | Apoplexy treating medicine composition | |
| CN1250228C (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
| CN1270762C (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN101032524A (en) | Application of martianus dermestoides in producing oxygen-deficient resisting medicine or healthy food and the preparing method | |
| CN1872186A (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
| CN116898897B (en) | Primordial qi-tonifying, hypoxia-resisting and chronic fatigue-conditioning primordial qi-preserving soup recipe and preparation method thereof | |
| CN1565554A (en) | Fat reducing Chinese drugs for treating simple obesity | |
| CN1839882A (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN1277553C (en) | Redy preparation Chinese medicine for treating kinetic fatigue and chronic fatigue syndrome | |
| CN107349303B (en) | Traditional Chinese medicine composition for treating chronic chest pain and application thereof | |
| CN1903184A (en) | Effervesce tablets for treating liver diseases | |
| CN1055239C (en) | Plaster for curing cough and asthma and its producing method | |
| CN1663600A (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| CN1235599C (en) | Arsenic compound recipe for treating tuberculosis and dermatopathy | |
| CN1112204C (en) | Traditional Chinese powder medicine for treating cough and preparation process thereof | |
| CN1872234A (en) | Composition of medication for inducing diuresis to alleviate edema, preparing and controlling quality method, usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |